6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn's disease.
Two large studies concluded that AZA started early after diagnosis of Crohn's disease have no late maintenance value. This is contrary to previous studies on 6MP for Crohn's disease and could lead to negating the value of two of the few drugs that have been proven successful. We here outline the many reasons why 6MP remains a valuable drug in the treatment of Crohn's disease.
Gastroenterology, Lenox Hill Hospital, New York, NY, United States; New York University School of Medicine, United States. Electronic address: bkorelitz@nshs.edu.
Burton I
BI
Korelitz
ICAHN School of Medicine at Mount Sinai Hospital, New York, NY, United States.
Daniel H
DH
Present
D001379:Azathioprine / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015122:Mercaptopurine / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D001379:Azathioprine
6-Mercaptopurine; Azathioprine; Crohn's disease